Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Iovance Biotherapeutics, Inc. - Common Stock
(NQ:
IOVA
)
2.790
-0.060 (-2.11%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 29, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Iovance Biotherapeutics, Inc. - Common Stock
< Previous
1
2
...
16
17
18
19
20
21
22
23
Next >
Analyst Expectations for Iovance Biotherapeutics's Future
↗
March 27, 2023
Via
Benzinga
Why Motorsport Games Shares Are Trading Lower By Over 10%; Here Are 20 Stocks Moving Premarket
↗
March 27, 2023
Gainers Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) shares rose 38.5% to $2.05 in pre-market trading after gaining 8% on Friday.
Via
Benzinga
First Republic Bank, KeyCorp And Other Big Stocks Moving Higher In Monday's Pre-Market Session
↗
March 27, 2023
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
March 24, 2023
First TIL Therapy BLA Submission to U.S. Food and Drug Administration
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Expert Ratings for Iovance Biotherapeutics
↗
March 06, 2023
Via
Benzinga
The Latest Analyst Ratings for Iovance Biotherapeutics
↗
January 24, 2023
Via
Benzinga
What 6 Analyst Ratings Have To Say About Iovance Biotherapeutics
↗
December 09, 2022
Via
Benzinga
Iovance Biotherapeutics to Present at Upcoming Conferences
March 01, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
February 28, 2023
First Biologics License Application (BLA) Submission on Track to Complete in 1Q23
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023
February 21, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
What 4 Analyst Ratings Have To Say About Iovance Biotherapeutics
↗
November 21, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
↗
January 27, 2023
Via
Benzinga
American Express, Visa And Other Big Stocks Moving Higher In Friday's Pre-Market Session
↗
January 27, 2023
U.S. stock futures traded slightly lower this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Why Iovance Biotherapeutics Stock Soared 12% Higher Today
↗
January 23, 2023
A business, clinical, and regulatory update lifted the spirits of investors.
Via
The Motley Fool
Iovance Biotherapeutics Acquires Clinigen's IL-2 Product For Upfront £166.7M
↗
January 23, 2023
Via
Benzinga
Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates
January 23, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Why Is Iovance Biotherapeutics (IOVA) Stock Soaring 20% Today?
↗
December 05, 2022
Although Iovance Biotherapeutics cuts a speculative figure, IOVA stock managed to skyrocket on Monday off insider buying.
Via
InvestorPlace
Why Iovance Biotherapeutics Shares Are Trading Higher By Around 19%? Here Are 40 Stocks Moving In Monday's Mid-Day Session
↗
December 05, 2022
Gainers Winc, Inc. (NYSE: WBEV) rose 88.5% to $0.3901 after dropping over 23% on Friday. Winc, last month, posted a Q3 loss of $0.33 per share.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
December 05, 2022
Via
Benzinga
US Stocks Start Week On Lower Note; Dow Tumbles 250 Points
↗
December 05, 2022
U.S. stocks traded lower this morning, with the Dow Jones falling around 250 points on Monday.
Via
Benzinga
Iovance Biotherapeutics Stock Is Surging: Here's Why
↗
December 05, 2022
Iovance Biotherapeutics Inc (NASDAQ: IOVA) shares are trading higher Monday following recent insider buying from Director Wayne Rothbaum.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
December 05, 2022
Via
Benzinga
$65 Million Bet On Iovance Biotherapeutics? Check Out These 3 Stocks Insiders Are Buying
↗
December 05, 2022
Although US stocks closed mixed on Friday, there were a few notable insider trades.
Via
Benzinga
Iovance Biotherapeutics to Present at Upcoming Conferences
November 30, 2022
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
NIO To Surge Around 105%? Plus Keybanc Predicts $165 For This Stock
↗
November 21, 2022
Keybanc raised the price target on AMETEK, Inc. (NYSE: AME) from $145 to $165. Keybanc analyst Steve Barger maintained an Overweight rating on the stock. AMETEK shares rose 0.9% to close at $139.32 on...
Via
Benzinga
Why Iovance Biotherapeutics Is Crashing Today
↗
November 18, 2022
The FDA is asking the drug development outfit for more information regarding its tumor-infiltrating lymphocyte therapy.
Via
The Motley Fool
Iovance Biotherapeutics Pushes FDA Rolling Submission Deadline Into Next Year For Its Lead Skin Cancer Candidate
↗
November 18, 2022
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
November 18, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
↗
November 18, 2022
It's time to start closing out the trading week with a dive into the biggest pre-market stock movers for Friday morning!
Via
InvestorPlace
Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma
November 18, 2022
BLA Submission Ongoing with U.S. Food and Drug Administration
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
...
16
17
18
19
20
21
22
23
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.